Developer docs
API playgroundTry for free, no card

Search company profiles

iVascular

Full company profile

uuid000b9u6

Namestring
iVascular
Legal namestring
iVascular, S.L.U.
Company typeenum
Private
Founded yearint
2010
Descriptiontext

iVascular, S.L.U. is a Barcelona-based, founder-led medical device company founded in 2010 that designs, manufactures and commercializes catheter-based cardiovascular devices — drug-eluting stents (DES), drug-coated balloons (DCB), support catheters, microcatheters, aspiration catheters and stent retrievers — for coronary, peripheral and neurovascular indications. All products are produced at its vertically integrated Sant Vicenç dels Horts facility ('100% Made in Europe'), with the company's competitive differentiation resting on proprietary nanocoatings and encapsulation chemistries: TransferTech (Luminor DCB), TransferWise (Angiolite DES), CoverTech (iCover covered stent) and Hydrax Plus (neuro catheters). The portfolio spans 18+ commercialized SKUs across three therapeutic areas, supplemented by a clinical pipeline that includes the OPAL first-in-human study of the Amber radiopaque embolic liquid.

The company operates a hybrid go-to-market model: direct enterprise field sales to interventional cardiologists, vascular surgeons, interventional radiologists and tertiary hospitals, complemented by country-specific distribution partnerships (e.g., Medico's Hirata in Japan) and clinical-evidenced demand generation via a portfolio of 12+ registered trials and proprietary medical congresses (iVS Barcelona, Latam, Osaka). Reimbursement has been secured for Luminor DCB in France (2019) and Angiolite DES in Belgium (2020), with regulatory approvals across the EU, Japan (MHLW, 2025), India (2017), and broader Latin America. Physician engagement is reinforced by the iCardio Grant, iVascular Grant and UAB Research Chair programs.

Revenue mechanics are quote-based hardware sales to hospitals, healthcare systems and distributors; pricing is not publicly disclosed. Notable customers are tertiary and academic centers (Hospital Clinic Barcelona, Hospital La Fe, Kokura Memorial, ICBA Buenos Aires, University Hospital Jena), which function both as commercial reference sites and as Principal Investigator sites for the company's evidence-generation engine. The company is privately held with 51–100 employees and no disclosed funding rounds, suggesting bootstrapped or self-financed growth to date.

Short descriptiontext

iVascular is a Barcelona-based, privately held medical device company founded in 2010 that designs and manufactures vertically integrated drug-eluting stents, drug-coated balloons and catheters for coronary, peripheral and neurovascular interventions, sold to tertiary hospitals and specialist physicians across Europe, Asia and Latin America.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersFreiburg Im Breisgau, Germany
HQ citystring
Freiburg Im Breisgau
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug-eluting stents, drug-coated balloons, cardiovascular medical devices, peripheral vascular catheters, neurovascular thrombectomy devices
Industry2 codes
SECONDARYHLAHAFAA
Coronary Stents & Drug-Eluting Technologies
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
SECONDARYHLAHAFAJ
Thrombectomy, Embolic Protection & Stroke Intervention Devices
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Interventional Cardiology & Endovascular Medical Devices
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical device sales
TypeHardware Sales
Description

iVascular generates revenue primarily through one-time sales of its cardiovascular medical devices (drug-eluting stents, drug-coated balloons, and catheters) to hospitals, healthcare systems, and distributors. Sales are made directly via a sales force and indirectly via distribution partners such as Medico's Hirata in Japan.

ivascular.global
2Reimbursed product sales (Europe)
TypeHardware Sales
Description

iVascular's Luminor DCB and Angiolite DES have achieved reimbursement in multiple European countries including France (Luminor DCB since 2019) and Belgium (Angiolite DES since 2020), enabling recurring institutional revenue from hospital purchasers.

ivascular.global
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 20 records shown
1Angiolite
Description

Sirolimus-eluting coronary stent (DES) for treating stenotic and restenotic coronary lesions; Angiolite BTK variant for below-the-knee procedures.

ivascular.global
+19 more records
Core offering1 text field

iVascular designs, develops and manufactures catheter-based cardiovascular medical devices—including drug-eluting stents (DES), drug-coated balloons (DCB) and microcatheters/aspiration catheters—for the endovascular treatment of coronary, peripheral and neurovascular disease, all produced at its vertically integrated "100% Made in Europe" facility in Barcelona, Spain. Its portfolio is organized across three therapeutic areas (Coronary, Peripheral, Neurointerventionism) and is differentiated by proprietary nanocoating and encapsulation technologies (TransferTech, TransferWise, CoverTech, Hydrax Plus). The company sells these devices to hospitals and physicians through direct enterprise sales and regional distribution partners, supported by an active clinical-trial program (12+ registered trials) and physician education initiatives such as the Interactive Vascular Summit (iVS).

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 94.9% primary patency at 12 months in SOL Japan trial of Luminor DCB
+6 more records
Product overview1 text field

iVascular, S.L.U. is a Barcelona-based medical device company (100% Made in Europe) offering a vertically integrated portfolio of catheter-based, drug-eluting, and coated devices for the endovascular treatment of vascular disease. Its offering is organized as a platform-plus-modules architecture along three therapeutic areas — Coronary (Angiolite DES, Angiolite BTK DES, Essential pro DCB, Capturer, Naviscore, Navitian microcatheter, NC xperience, Xperience pro), Peripheral (Luminor DCB in 14/18/35 platforms, iVolution pro nitinol stent, iCover covered stent, Oceanus, Restorer, Sergeant support catheter), and Neurointerventionism (iNedit distal-access balloon catheter, iNdeep microcatheter family, iNtercept stent retriever, iNstroke 4F and 6F aspiration catheters). Cross-cutting proprietary technologies — TransferTech and TransferWise nanocoatings, CoverTech encapsulation, and Hydrax Plus hydrophilic coating — differentiate the device families, while the pipeline includes the Amber radiopaque embolic liquid (in OPAL first-in-human study). The portfolio is supported by education programs including the iCardio Grant, iVascular Grant, and the interactive Vascular Summit (iVS) congress series.

Product and service5 records
1Angiolite (coronary)
CategoryCoronary drug-eluting stent (DES)
Description

Sirolimus-eluting cobalt-chromium coronary stent on a rapid-exchange platform with iVascular's proprietary TransferWise fluoropolymer nanocoating and alternating links for homogeneous arterial coverage and high endothelization rates; indicated for stenotic, restenotic and occlusive lesions in coronary arteries, with 44 and 49 mm lengths available for diffuse disease.

2Angiolite BTK
CategoryPeripheral drug-eluting stent (DES) for below-the-knee
Description

Sirolimus-eluting stent variant of Angiolite designed for below-the-knee (BTK) peripheral procedures, with safety and feasibility in BTK interventions demonstrated in the ANGIOLITE BTK Trial.

3Essential pro
CategoryCoronary drug-coated balloon (DCB)
Description

Paclitaxel drug-coated balloon for coronary applications including in-stent restenosis (ISR) and small vessels, demonstrating high deliverability, low target-lesion revascularization and minimal adverse events in clinical studies.

4iCover
CategoryPeripheral balloon-expandable covered stent
Description

Balloon-expandable covered stent for renal and iliac arteries, aneurysms and ruptures, encapsulating ePTFE layers via iVascular's patented CoverTech technology; features tantalum radiopaque markers and high flexibility for tortuous vessels.

5iVolution pro
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeGTM or Marketing PartnerAnnounced on2025-01-01
Description

Scientific Committee of KOLs who evaluate cases for the iCardio Grant competition: Dr. Roberto Garbo (Maria Pia Hospital, GVM Turin), Dr. Maciej Lesiak (Poznan University of Medical Sciences), Dr. Kambis Mashayekhi (MediClin Herzzentrum Lahr), Dr. Soledad Ojeda (Hospital Reina Sofía, Córdoba), Dr. Antoni Serra (Hospital Sant Pau i Santa Creu, Barcelona).

2Hospital La Fe, Valencia (Dr. Fernando Gomez)
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-11-11
Description

Dr. Fernando Gomez leads the OPAL study of iVascular's new embolic liquid Amber in collaboration with 10 Spanish centers specialized in embolization. The study enrolls 70 patients requiring peripheral embolization across indications including vascular anomalies, hemorrhages, aneurysms, pseudoaneurysms, type II endoleaks, varicose veins, portal veins, hypervascular tumors, and pathological organs.

ivascular.global
3Universitat Autònoma de Barcelona (UAB)
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-04-17
Description

iVascular established the Research Chair in Surgery at the UAB Faculty of Medicine led by Prof. José María Balibrea. Activities include studies in robotic surgery and an international training course on innovation and value creation in surgical research, culminating in the 'School of Innovation in Surgery.' Dean Prof. Salvador Navarro Soto endorsed the public-private alliance.

ivascular.global
Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2024-01-18
Description

Dr. Manel Sabaté (Head of Interventional Cardiology at Hospital Clinic Barcelona) is the Principal Investigator of the ANGIODAPT trial, a 2x2 factorial, all-comer, multicenter RCT evaluating abbreviated DAPT post-Angiolite DES implantation. The trial involves 2,312 patients across 40 sites in Spain, Belgium and France with 5-year follow-up. Steering committee includes Dr. Rodés, Dr. Brugaletta, Dr. Ortega, Dr. Dewilde and Dr. Garot.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

Strategic research collaboration to advance innovation in surgery, including robotic surgery studies and creation of the 'School of Innovation in Surgery' to train healthcare professionals with global figures in research.

6Medico's Hirata
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-04-15
Description

iVascular partners with Medico's Hirata, a Japanese medical device company, to distribute Luminor DCB in Japan. The alliance began with the SOL-Japan clinical trial (April 2021) and culminated in Luminor DCB receiving MHLW approval (May 2025), with a Japan-specific Luminor 18 RX version developed for the Japanese market. The partnership represents a strategic entry into Japan (~1.7% of world population).

ivascular.global
Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian privately held medical device company with coronary (Metafor sirolimus DES) and peripheral (Praza DCB) franchises, comparable vertically integrated manufacturing model and similar scale, competing in many of the same emerging markets as iVascular.

2MicroPort Scientific
TypeDirect peer
Description

Chinese-headquartered medical device group with coronary DES (Firehawk, Firebird) and peripheral DCB/stent franchises; comparable vertically integrated business model and product breadth across coronary and peripheral vascular indications.

TypeDirect peer
Description

US-based neurovascular and peripheral thrombectomy specialist whose aspiration catheters and stent retrievers directly overlap with iVascular's iNstroke and iNtercept neurointervention portfolio, addressing the same acute ischemic stroke call points.

TypeBroad incumbent
Description

Independent (post-Cardinal Health spinout) global interventional cardiovascular business offering stents, DCBs and catheters; overlaps with iVascular's coronary and peripheral portfolios and competes for the same hospital procurement budgets, but at significantly larger scale.

TypeBroad incumbent
Description

Japanese global medical device incumbent with a substantial interventional systems division (peripheral and coronary DCBs, stents and access devices) that competes with iVascular in peripheral intervention and is a logical Japanese-market competitor following iVascular's Luminor launch in Japan.

TypeDirect peer
Description

Privately held German manufacturer of coronary stents (Orsiro), peripheral devices and electrophysiology implants, with a similar vertically integrated European manufacturing footprint and comparable mid-cap scale and product breadth across vascular indications.

TypeBroad incumbent
Description

Through its Neurovascular division (Trevo, AXS), Stryker competes directly with iVascular's iNstroke aspiration catheters, iNtercept stent retriever and iNdeep microcatheters in the acute ischemic stroke market, with substantially larger sales and clinical evidence resources.

8Acotec Scientific
TypeDirect peer
Description

Chinese DCB-focused medical device company whose peripheral (Orchid) and coronary drug-coated balloons directly compete with iVascular's Luminor and Essential pro franchises, with similar mid-cap scale and emerging global expansion.

9Balton
TypeRegional player
Description

Polish interventional cardiology and peripheral device manufacturer with a similar mid-cap profile and European focus; competes with iVascular primarily in Central and Eastern European hospital tenders rather than globally.

TypeEmerging player
Description

US-based medical device coating and drug-delivery company whose proprietary hydrophilic and drug-coating technologies overlap with iVascular's TransferTech and Hydrax Plus platforms, and which supplies/sells into the peripheral DCB ecosystem where iVascular competes.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance8 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

iVascular

Interventional Cardiology & Endovascular Medical Devicesivascular.global

iVascular is a Barcelona-based, privately held medical device company founded in 2010 that designs and manufactures vertically integrated drug-eluting stents, drug-coated balloons and catheters for coronary, peripheral and neurovascular interventions, sold to tertiary hospitals and specialist physicians across Europe, Asia and Latin America.

What iVascular does

iVascular, S.L.U. is a Barcelona-based, founder-led medical device company founded in 2010 that designs, manufactures and commercializes catheter-based cardiovascular devices — drug-eluting stents (DES), drug-coated balloons (DCB), support catheters, microcatheters, aspiration catheters and stent retrievers — for coronary, peripheral and neurovascular indications. All products are produced at its vertically integrated Sant Vicenç dels Horts facility ('100% Made in Europe'), with the company's competitive differentiation resting on proprietary nanocoatings and encapsulation chemistries: TransferTech (Luminor DCB), TransferWise (Angiolite DES), CoverTech (iCover covered stent) and Hydrax Plus (neuro catheters). The portfolio spans 18+ commercialized SKUs across three therapeutic areas, supplemented by a clinical pipeline that includes the OPAL first-in-human study of the Amber radiopaque embolic liquid.

The company operates a hybrid go-to-market model: direct enterprise field sales to interventional cardiologists, vascular surgeons, interventional radiologists and tertiary hospitals, complemented by country-specific distribution partnerships (e.g., Medico's Hirata in Japan) and clinical-evidenced demand generation via a portfolio of 12+ registered trials and proprietary medical congresses (iVS Barcelona, Latam, Osaka). Reimbursement has been secured for Luminor DCB in France (2019) and Angiolite DES in Belgium (2020), with regulatory approvals across the EU, Japan (MHLW, 2025), India (2017), and broader Latin America. Physician engagement is reinforced by the iCardio Grant, iVascular Grant and UAB Research Chair programs.

Revenue mechanics are quote-based hardware sales to hospitals, healthcare systems and distributors; pricing is not publicly disclosed. Notable customers are tertiary and academic centers (Hospital Clinic Barcelona, Hospital La Fe, Kokura Memorial, ICBA Buenos Aires, University Hospital Jena), which function both as commercial reference sites and as Principal Investigator sites for the company's evidence-generation engine. The company is privately held with 51–100 employees and no disclosed funding rounds, suggesting bootstrapped or self-financed growth to date.

iVascular firmographics

Firmographics
Name
iVascular
Legal name
iVascular, S.L.U.
Website
https://ivascular.global
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
251–500 employees
Short description
iVascular is a Barcelona-based, privately held medical device company founded in 2010 that designs and manufactures vertically integrated drug-eluting stents, drug-coated balloons and catheters for coronary, peripheral and neurovascular interventions, sold to tertiary hospitals and specialist physicians across Europe, Asia and Latin America.
Ownership category
akta.pro rank

Where iVascular is headquartered

Location

Headquarters

HQ city
Freiburg Im Breisgau
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

iVascular business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure

Revenue model

  1. Medical device sales: iVascular generates revenue primarily through one-time sales of its cardiovascular medical devices (drug-eluting stents, drug-coated balloons, and catheters) to hospitals, healthcare systems, and distributors. Sales are made directly via a sales force and indirectly via distribution partners such as Medico's Hirata in Japan.
  2. Reimbursed product sales (Europe): iVascular's Luminor DCB and Angiolite DES have achieved reimbursement in multiple European countries including France (Luminor DCB since 2019) and Belgium (Angiolite DES since 2020), enabling recurring institutional revenue from hospital purchasers.

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

iVascular product offering

Product offering

Core offering

iVascular designs, develops and manufactures catheter-based cardiovascular medical devices—including drug-eluting stents (DES), drug-coated balloons (DCB) and microcatheters/aspiration catheters—for the endovascular treatment of coronary, peripheral and neurovascular disease, all produced at its vertically integrated "100% Made in Europe" facility in Barcelona, Spain. Its portfolio is organized across three therapeutic areas (Coronary, Peripheral, Neurointerventionism) and is differentiated by proprietary nanocoating and encapsulation technologies (TransferTech, TransferWise, CoverTech, Hydrax Plus). The company sells these devices to hospitals and physicians through direct enterprise sales and regional distribution partners, supported by an active clinical-trial program (12+ registered trials) and physician education initiatives such as the Interactive Vascular Summit (iVS).

Product overview

iVascular, S.L.U. is a Barcelona-based medical device company (100% Made in Europe) offering a vertically integrated portfolio of catheter-based, drug-eluting, and coated devices for the endovascular treatment of vascular disease. Its offering is organized as a platform-plus-modules architecture along three therapeutic areas — Coronary (Angiolite DES, Angiolite BTK DES, Essential pro DCB, Capturer, Naviscore, Navitian microcatheter, NC xperience, Xperience pro), Peripheral (Luminor DCB in 14/18/35 platforms, iVolution pro nitinol stent, iCover covered stent, Oceanus, Restorer, Sergeant support catheter), and Neurointerventionism (iNedit distal-access balloon catheter, iNdeep microcatheter family, iNtercept stent retriever, iNstroke 4F and 6F aspiration catheters). Cross-cutting proprietary technologies — TransferTech and TransferWise nanocoatings, CoverTech encapsulation, and Hydrax Plus hydrophilic coating — differentiate the device families, while the pipeline includes the Amber radiopaque embolic liquid (in OPAL first-in-human study). The portfolio is supported by education programs including the iCardio Grant, iVascular Grant, and the interactive Vascular Summit (iVS) congress series.

Differentiator

Problem solved

Functional benefit

Brands

  • Angiolite: Sirolimus-eluting coronary stent (DES) for treating stenotic and restenotic coronary lesions; Angiolite BTK variant for below-the-knee procedures.
  • Luminor
  • essential pro
  • iVolution pro
  • iCover
  • Oceanus
  • Sergeant
  • Restorer
  • Navitian
  • Naviscore
  • Capturer
  • NC Xperience
  • Xperience pro
  • Angiolite BTK
  • iNedit
  • iNdeep
  • iNtercept
  • iNstroke 4F
  • iNstroke 6F
  • Amber

Products and services

  • Angiolite (coronary) Sirolimus-eluting cobalt-chromium coronary stent on a rapid-exchange platform with iVascular's proprietary TransferWise fluoropolymer nanocoating and alternating links for homogeneous arterial coverage and high endothelization rates; indicated for stenotic, restenotic and occlusive lesions in coronary arteries, with 44 and 49 mm lengths available for diffuse disease.
  • Angiolite BTK Sirolimus-eluting stent variant of Angiolite designed for below-the-knee (BTK) peripheral procedures, with safety and feasibility in BTK interventions demonstrated in the ANGIOLITE BTK Trial.
  • Essential pro Paclitaxel drug-coated balloon for coronary applications including in-stent restenosis (ISR) and small vessels, demonstrating high deliverability, low target-lesion revascularization and minimal adverse events in clinical studies.
  • iCover Balloon-expandable covered stent for renal and iliac arteries, aneurysms and ruptures, encapsulating ePTFE layers via iVascular's patented CoverTech technology; features tantalum radiopaque markers and high flexibility for tortuous vessels.
  • iVolution pro

Quantifiable outcome

  • 94.9% primary patency at 12 months in SOL Japan trial of Luminor DCB
  • +6 more outcomes

Companies that use iVascular

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

iVascular technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

iVascular partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and flagship.

  • iCardio Grant Scientific CommitteecoreGTM or Marketing Partner · 1 January 2025Scientific Committee of KOLs who evaluate cases for the iCardio Grant competition: Dr. Roberto Garbo (Maria Pia Hospital, GVM Turin), Dr. Maciej Lesiak (Poznan University of Medical Sciences), Dr. Kambis Mashayekhi (MediClin Herzzentrum Lahr), Dr. Soledad Ojeda (Hospital Reina Sofía, Córdoba), Dr. Antoni Serra (Hospital Sant Pau i Santa Creu, Barcelona).
  • Hospital La Fe, Valencia (Dr. Fernando Gomez)coreImplementation/ SI/ Consulting Partner · 11 November 2024Dr. Fernando Gomez leads the OPAL study of iVascular's new embolic liquid Amber in collaboration with 10 Spanish centers specialized in embolization. The study enrolls 70 patients requiring peripheral embolization across indications including vascular anomalies, hemorrhages, aneurysms, pseudoaneurysms, type II endoleaks, varicose veins, portal veins, hypervascular tumors, and pathological organs.
  • Universitat Autònoma de Barcelona (UAB)flagshipStrategic or Co-development Partner · 17 April 2024iVascular established the Research Chair in Surgery at the UAB Faculty of Medicine led by Prof. José María Balibrea. Activities include studies in robotic surgery and an international training course on innovation and value creation in surgical research, culminating in the 'School of Innovation in Surgery.' Dean Prof. Salvador Navarro Soto endorsed the public-private alliance.
  • Hospital Clinic Barcelona (Dr. Manel Sabaté)coreImplementation/ SI/ Consulting Partner · 18 January 2024Dr. Manel Sabaté (Head of Interventional Cardiology at Hospital Clinic Barcelona) is the Principal Investigator of the ANGIODAPT trial, a 2x2 factorial, all-comer, multicenter RCT evaluating abbreviated DAPT post-Angiolite DES implantation. The trial involves 2,312 patients across 40 sites in Spain, Belgium and France with 5-year follow-up. Steering committee includes Dr. Rodés, Dr. Brugaletta, Dr. Ortega, Dr. Dewilde and Dr. Garot.
  • Universitat Autònoma de Barcelona - Research Chair in SurgeryflagshipStrategic or Co-development Partner · 1 January 2024Strategic research collaboration to advance innovation in surgery, including robotic surgery studies and creation of the 'School of Innovation in Surgery' to train healthcare professionals with global figures in research.
  • Medico's HirataflagshipChannel Partner/ Reseller/ Distributor · 15 April 2021iVascular partners with Medico's Hirata, a Japanese medical device company, to distribute Luminor DCB in Japan. The alliance began with the SOL-Japan clinical trial (April 2021) and culminated in Luminor DCB receiving MHLW approval (May 2025), with a Japan-specific Luminor 18 RX version developed for the Japanese market. The partnership represents a strategic entry into Japan (~1.7% of world population).

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

iVascular competitors and assessment

Company assessment

Direct peers

  • Meril Life Sciences: Indian privately held medical device company with coronary (Metafor sirolimus DES) and peripheral (Praza DCB) franchises, comparable vertically integrated manufacturing model and similar scale, competing in many of the same emerging markets as iVascular.
  • MicroPort Scientific: Chinese-headquartered medical device group with coronary DES (Firehawk, Firebird) and peripheral DCB/stent franchises; comparable vertically integrated business model and product breadth across coronary and peripheral vascular indications.
  • Penumbra: US-based neurovascular and peripheral thrombectomy specialist whose aspiration catheters and stent retrievers directly overlap with iVascular's iNstroke and iNtercept neurointervention portfolio, addressing the same acute ischemic stroke call points.
  • BIOTRONIK: Privately held German manufacturer of coronary stents (Orsiro), peripheral devices and electrophysiology implants, with a similar vertically integrated European manufacturing footprint and comparable mid-cap scale and product breadth across vascular indications.
  • Acotec Scientific: Chinese DCB-focused medical device company whose peripheral (Orchid) and coronary drug-coated balloons directly compete with iVascular's Luminor and Essential pro franchises, with similar mid-cap scale and emerging global expansion.

Broad incumbents

  • Cordis: Independent (post-Cardinal Health spinout) global interventional cardiovascular business offering stents, DCBs and catheters; overlaps with iVascular's coronary and peripheral portfolios and competes for the same hospital procurement budgets, but at significantly larger scale.
  • Terumo: Japanese global medical device incumbent with a substantial interventional systems division (peripheral and coronary DCBs, stents and access devices) that competes with iVascular in peripheral intervention and is a logical Japanese-market competitor following iVascular's Luminor launch in Japan.
  • Stryker (Neurovascular): Through its Neurovascular division (Trevo, AXS), Stryker competes directly with iVascular's iNstroke aspiration catheters, iNtercept stent retriever and iNdeep microcatheters in the acute ischemic stroke market, with substantially larger sales and clinical evidence resources.

Regional players

  • Balton: Polish interventional cardiology and peripheral device manufacturer with a similar mid-cap profile and European focus; competes with iVascular primarily in Central and Eastern European hospital tenders rather than globally.

Emerging players

  • Surmodics: US-based medical device coating and drug-delivery company whose proprietary hydrophilic and drug-coating technologies overlap with iVascular's TransferTech and Hydrax Plus platforms, and which supplies/sells into the peripheral DCB ecosystem where iVascular competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

iVascular social profiles

Digital presence

iVascular compliance and trust

Trust signal

Compliance8 records

iVascular financial estimates

Financial estimate

Revenue estimate

Valuation estimate

iVascular leadership team

Management profile

Number of profiles

Profiles2 records

iVascular funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

iVascular M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about iVascular

What does iVascular do?

iVascular designs, develops and manufactures catheter-based cardiovascular medical devices—including drug-eluting stents (DES), drug-coated balloons (DCB) and microcatheters/aspiration catheters—for the endovascular treatment of coronary, peripheral and neurovascular disease, all produced at its vertically integrated "100% Made in Europe" facility in Barcelona, Spain. Its portfolio is organized across three therapeutic areas (Coronary, Peripheral, Neurointerventionism) and is differentiated by proprietary nanocoating and encapsulation technologies (TransferTech, TransferWise, CoverTech, Hydrax Plus). The company sells these devices to hospitals and physicians through direct enterprise sales and regional distribution partners, supported by an active clinical-trial program (12+ registered trials) and physician education initiatives such as the Interactive Vascular Summit (iVS).

Is iVascular a public or private company?

iVascular is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was iVascular founded?

iVascular was founded in 2010. It employs 251 to 500 people.

Where is iVascular based?

iVascular is headquartered in Freiburg Im Breisgau, Germany, in the Europe region.

How does iVascular make money?

Two revenue lines are on record. Medical device sales are the primary driver. The others are reimbursed product sales (Europe).

Who are iVascular's main competitors?

Direct peers on record are Meril Life Sciences, MicroPort Scientific, Penumbra, BIOTRONIK and Acotec Scientific. Broad incumbents are Cordis, Terumo and Stryker (Neurovascular). Balton is listed as a regional player. Surmodics is listed as an emerging player.

Does iVascular have an API?

No public API is recorded for iVascular.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals